A 53-year-old man with a myocardial infarct and thromboses after coronary-artery bypass grafting

New England Journal of Medicine

Volumn 346, Issue 20, 2002, Pages 1562-1570

  Aird, W C ^a   Mark, E J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; ANTICOAGULANT AGENT;

ADULT; ANGIOGRAPHY; AORTA BALLOON; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ELECTROCARDIOGRAM; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; ST SEGMENT; THROMBOCYTOPENIA; THROMBOSIS; WHITE CLOT SYNDROME; ARTERY; CHEMICALLY INDUCED DISORDER; CLINICAL OBSERVATION; CLINICAL STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIAGNOSIS; FATALITY; HEART MUSCLE; INFARCTION; KIDNEY; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; VASCULARIZATION;

ANTICOAGULANTS; ARTERIES; CORONARY ARTERY BYPASS; CORONARY DISEASE; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; HEPARIN; HUMANS; INFARCTION; KIDNEY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; THROMBOCYTOPENIA; THROMBOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037118281     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcpc020015     Document Type: Article

References (26)

1. Association of thrombocytopenia with the use of intra-aortic balloon pumps
2. Vascular-bed-specific hemostasis and hypercoagulable states
3. Hypercoagulability in venous and arterial thrombosis
4. Cholesterol emboli syndrome
5. Ischaemic complications with intra-aortic balloon counter pulsation: Incidence and management
6. Heparin-induced thrombocytopenia: A ten-year retrospective
7. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
8. Immunoglobin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
9. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
10. Temporal aspects of heparin-induced thrombocytopenia
11. Impact of the patient population on the risk for heparin-induced thrombocytopenia
12. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: Clinical implications for heparin-induced thrombocytopenia
13. Clinical presentation of heparin-induced thrombocytopenia
14. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
15. A 14-year study of heparin-induced thrombocytopenia
16. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
17. Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution
18. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
19. Acute limb ischemia and heparin-induced thrombocytopenia: The value of echocardiography in eliminating a cardiac source of arterial emboli
20. History of heparin-induced thrombocytopenia
21. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia
22. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome
23. Heparin-induced thrombocytopenia with thromboembolic complications: Metaanalysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
24. New treatment options for heparin-induced thrombocytopenia
25. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery
26. Improved laboratory confirmation of heparin-induced thrombocytopenia type II: Time course of antibodies and combination of antigen and biologic assays